Direct comparison of (+/-) 3,4-methylenedioxymethamphetamine ("ecstasy") disposition and metabolism in squirrel monkeys and humans.
The present study compared the disposition and metabolism of the recreational drug (+/-) 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") in squirrel monkeys and humans because the squirrel monkey has been extensively studied for MDMA neurotoxicity. A newly developed liquid chromatography-mass spectrometric procedure for simultaneous measurement of MDMA, 3,4-dihydroxymethamphetamine, 4-hydroxy-3-methoxymethamphetamine, and 3,4-methylenedioxyamphetamine was employed. In both humans and squirrel monkeys, a within-subject design permitted testing of different doses in the same subjects. Humans and squirrel monkeys were found to metabolize MDMA in similar, but not identical, pathways and proportions. In particular, amounts of 3,4-dihydroxymethamphetamine (after conjugate cleavage) and 3,4-methylenedioxyamphetamine were similar in the 2 species, but formation of 4-hydroxy-3-methoxymethamphetamine was greater in squirrel monkeys than in humans. Both species demonstrated nonlinear MDMA pharmacokinetics at comparable plasma MDMA concentrations (125-150 ng/mL and above). The elimination half-life of MDMA was considerably shorter in squirrel monkeys than in humans (2-3 versus 6-9 hours). In both species, there was substantial individual variability. These results suggest that the squirrel monkey may be a useful model for predicting outcomes of MDMA exposure in humans, although this will also depend on the degree to which MDMA pharmacodynamics in the squirrel monkey parallels that in humans.
Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, USA.
Melanie
M
Mueller
Erin A
EA
Kolbrich
Frank T
FT
Peters
Hans H
HH
Maurer
Una D
UD
McCann
Marilyn A
MA
Huestis
George A
GA
Ricaurte
D015104:3,4-Methylenedioxyamphetamine / Q000097:blood*; D000293:Adolescent; D000818:Animals; D001921:Brain / Q000378:metabolism*; D002851:Chromatography, High Pressure Liquid; D016903:Drug Monitoring; D005260:Female; D000882:Haplorhini; D006801:Humans; D008297:Male; D053858:Metabolic Networks and Pathways; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000097:blood* / Q000493:pharmacokinetics; D020258:Neurotoxicity Syndromes; D012453:Saimiri; D012701:Serotonin / Q000378:metabolism; D021241:Spectrometry, Mass, Electrospray Ionization; D055815:Young Adult
D012701:Serotonin; D015104:3,4-Methylenedioxyamphetamine; D018817:N-Methyl-3,4-methylenedioxyamphetamine